Reviewing Alterity Therapeutics Limited (ATHE)’s and DelMar Pharmaceuticals Inc. (NASDAQ:DMPI)’s results

Alterity Therapeutics Limited (NASDAQ:ATHE) and DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alterity Therapeutics Limited N/A 0.00 N/A -0.78 0.00
DelMar Pharmaceuticals Inc. N/A 0.00 7.95M -3.99 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Alterity Therapeutics Limited and DelMar Pharmaceuticals Inc.

Profitability

Table 2 provides the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Alterity Therapeutics Limited 0.00% -56.4% -49.9%
DelMar Pharmaceuticals Inc. 0.00% 628% -144.8%

Volatility and Risk

A 0.99 beta indicates that Alterity Therapeutics Limited is 1.00% less volatile compared to S&P 500. From a competition point of view, DelMar Pharmaceuticals Inc. has a 1.72 beta which is 72.00% more volatile compared to S&P 500.

Liquidity

The current Quick Ratio of Alterity Therapeutics Limited is 4.4 while its Current Ratio is 4.4. Meanwhile, DelMar Pharmaceuticals Inc. has a Current Ratio of 3.2 while its Quick Ratio is 3.2. Alterity Therapeutics Limited is better positioned to pay off its short-term and long-term debts than DelMar Pharmaceuticals Inc.

Institutional & Insider Ownership

Alterity Therapeutics Limited and DelMar Pharmaceuticals Inc. has shares owned by institutional investors as follows: 3.6% and 8.1%. Alterity Therapeutics Limited’s share owned by insiders are 18.7%. Competitively, 0.9% are DelMar Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alterity Therapeutics Limited -4.79% -14.05% -1.24% -10.67% -20.5% 24.22%
DelMar Pharmaceuticals Inc. -33.83% -36.4% -42.7% -61.65% -76.98% -35.36%

For the past year Alterity Therapeutics Limited has 24.22% stronger performance while DelMar Pharmaceuticals Inc. has -35.36% weaker performance.

Summary

Alterity Therapeutics Limited beats DelMar Pharmaceuticals Inc. on 5 of the 6 factors.

DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which has completed Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; collaboration agreement with the University of Texas MD Anderson Cancer Center; and collaboration agreement with Accurexa Inc. to develop a novel formulation for the local delivery of combination chemotherapy for the treatment of brain cancer and other solid tumors. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.